| dc.description.abstract | Age-related macular degeneration is one of the main causes of irreversible vision loss in developed countries in the population over 60 years old. Adropin is a newly recognized peptide hormone that has a regulatory function in insulin resistance, aging process and angiogenesis. In this study, our aim was to investigate the relationship between serum adropin in patients with wet type age-related macular degeneration compared to the healthy people.
Materials and methods This study consisted of two groups, 45 included wet-type AMD patients (Cases) and 45 normal healthy individuals (Controls) who were selected to be similar in terms of age, sex, and body mass index (BMI). Patients with the diagnostic criteria for wet-type AMD in the case group such as bilateral changes in the macula including the presence of drusen, macular atrophy, and pigmentary changes, along with the choroidal neovascularization at least in one eye, who attended Nikookari hospital without any previous history of visual impairment, were included. Patients with co-morbidities such as diabetes, hypertension, autoimmune diseases, and a previous history of visual impairment; were excluded. . FBS, Hemoglobin A1C (HbA1C), lipid profile, and serum Adropin level were checked.
Findings: The mean serum adropin level of AMD patients was significantly lower compared to the control group (P < 0.001). Also, the mean of hsCRP (P=0.03) and HDL (P<0.001) were significantly higher in AMD patients. | en_US |
